Psyence Biomedical Ltd. Warrant
PBMWW$0.02 +0.00 (5.84%)
Company News
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
Psyence BioMed advanced its Phase IIb clinical trial for psilocybin-assisted psychotherapy in palliative care, secured nature-derived psilocybin and ibogaine supply, and positioned itself as a leader in longevity science research.
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'
U.S. stock futures declined ahead of the 'Triple Witching' hour, with the market expected to see the expiry of about $6.6 trillion options. Analysts have mixed views on the market's recovery by the end of the year.
